BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-116@catalystbrief.girapphe.com
DTSTAMP:20261117T181552Z
LAST-MODIFIED:20261117T181552Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Readout: Hangzhou Highlightll Pharmaceutical Co.\, Ltd — TLL-018 
 [Dec 2026]
DESCRIPTION:Phase 3 primary completion: A Long-term Extension Clinical Stud
 y of TLL-018 in Patients With Rheumatoid Arthritis.\nSource: https://clini
 caltrials.gov/study/NCT06887127\nhttps://catalystbrief.girapphe.com/e/116?
 lang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/116?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
